Large-scale functional expression of WT and truncated human adenosine A$_{2A}$ receptor in *Pichia pastoris* bioreactor cultures

Shweta Singh†1, Adrien Gras†1, Cédric Fiez-Vandal2,4, Jonathan Ruprecht1, Rohini Rana1, Magdalena Martinez1, Philip G Strange3, Renaud Wagner2 and Bernadette Byrne*1

**Abstract**

**Background:** The large-scale production of G-protein coupled receptors (GPCRs) for functional and structural studies remains a challenge. Recent successes have been made in the expression of a range of GPCRs using *Pichia pastoris* as an expression host. *P. pastoris* has a number of advantages over other expression systems including ability to post-translationally modify expressed proteins, relative low cost for production and ability to grow to very high cell densities. Several previous studies have described the expression of GPCRs in *P. pastoris* using shaker flasks, which allow culturing of small volumes (500 ml) with moderate cell densities (OD$_{600}$ ~15). The use of bioreactors, which allow straightforward culturing of large volumes, together with optimal control of growth parameters including pH and dissolved oxygen to maximise cell densities and expression of the target receptors, are an attractive alternative. The aim of this study was to compare the levels of expression of the human Adenosine 2A receptor (A$_{2A}$R) in *P. pastoris* under control of a methanol-inducible promoter in both flask and bioreactor cultures.

**Results:** Bioreactor cultures yielded an approximately five times increase in cell density (OD$_{600}$ ~75) compared to flask cultures prior to induction and a doubling in functional expression level per mg of membrane protein, representing a significant optimisation. Furthermore, analysis of a C-terminally truncated A$_{2A}$R, terminating at residue V334 yielded the highest levels (200 pmol/mg) so far reported for expression of this receptor in *P. pastoris*. This truncated form of the receptor was also revealed to be resistant to C-terminal degradation in contrast to the WT A$_{2A}$R, and therefore more suitable for further functional and structural studies.

**Conclusion:** Large-scale expression of the A$_{2A}$R in *P. pastoris* bioreactor cultures results in significant increases in functional expression compared to traditional flask cultures.

**Published:** 10 October 2008

**Received:** 28 August 2008

**Accepted:** 10 October 2008

© 2008 Singh et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background

G-protein-coupled receptors (GPCRs) form a large superfamily of cell-surface receptors that mediate cellular responses to a wide range of biologically active molecules including hormones, neurotransmitters and drugs. Indeed, half of all currently available pharmaceuticals act through GPCRs [1,2]. The physiological and pharmacological importance of these proteins makes them key targets for drug discovery programmes. Our understanding of the precise mechanism of action of these important proteins is currently limited by a lack of high-resolution structural data. One limiting factor to structural studies of GPCRs has, until recently, been low expression levels [3]. With the exception of rhodopsin, all GPCRs are expressed at very low levels endogenously, thus requiring the development of recombinant overexpression systems. Careful expression vector design, GPCR codon-optimisation [4] and high throughput approaches used to identify GPCRs with the highest expression levels in different expression systems [5] are among the methods that have been used to produce sufficiently high levels of functional GPCRs suitable for structural studies.

Success has been achieved when using the expression host Pichia pastoris for the production of membrane proteins for structural studies, most notably the rat membrane protein K⁺ channel [6]. Pichia has several advantages over other systems for the production of GPCRs. It is easy to manipulate, has high production levels and is relatively inexpensive. In addition, Pichia has the ability to glycosylate expressed receptors, albeit in a modified form compared to higher eukaryotes, which is essential for the proper functioning and membrane targeting of many receptors [7-10]. Much effort has been applied to the optimisation of Pichia expression systems specifically for GPCR production [11-16]. The basic system uses a pPIC9K vector (Invitrogen) where GPCR expression is under the control of the strong methanol inducible AOX1 promoter. Protease deficient expression strains, such as the SMD1163 strain, and the use of the α-factor leader sequence have improved receptor expression levels [11,12]. Modifications to the growth media including addition of histidine, receptor specific ligands and dimethyl sulfoxide, which facilitates phospholipid biosynthesis and membrane proliferation in yeast [17] have been shown to increase the expression levels of 20 different GPCRs in Pichia [15].

An additional advantage to the use of Pichia is that it readily adapts to large-scale culture in bioreactors [18]. Bioreactors allow precise regulation of the aeration, pH and addition of carbon source, which in turn allows the cultures to grow to ultra-high cell densities maximising expression of the target protein. However optimisation of standard protocols is usually necessary for specific targets. One particular issue is the amount of methanol added for induction. Indeed, very high levels of methanol can induce cytotoxic effects which reduce cell viability and thus expression [19]. Methanol sensors, which detect the level of unmetabolised methanol have been key to reducing these cytotoxic effects. Another important issue to consider is the osmotic stress induced during high cell density culturing which is known to be responsible for adaptive cell response mechanisms, such as changes in the membrane lipid content [20]. This may not be desirable in the process of membrane protein production and medium cell density culturing approach may appear more suitable. One aim of this study was to develop a protocol for the large scale expression of GPCRs in P. pastoris using bioreactors. The target GPCR used for development and characterisation of the protocol was the human Adenosine A2A receptor (A2AR), one of four receptors mediating the effects of adenosine. The A2AR is key in downregulation of immune responses in vivo and this in turn prevents inflammatory damage of healthy tissue [21]. In addition, it has been implicated in several serious conditions including cancer, Parkinson’s disease and asthma. A number of studies have previously shown heterologous expression of this receptor in a range of expression hosts including Escherichia coli [22], Pichia pastoris [16] and Saccharomyces cerevisiae [23]. The A2AR expressed in E. coli was sensitive to C-terminal proteolysis upon solubilisation [22]. Recent studies have shown the importance of removal of the unstructured C-terminal tail, among other modifications, in obtaining well diffracting crystals and ultimately structure determination of GPCRs [24,25]. The A2AR has a particularly long C-terminal tail, comprised of approximately 96 amino acid residues, likely to reduce the chances of obtaining well diffracting crystals. Therefore we also wished to assess the effects of generating a C-terminal truncation on the functional expression and stability of the receptor. A receptor construct was generated truncating the protein at valine 334 (V334), a residue corresponding to the end of the rhodopsin C-terminal tail.

Using a previously described vector system [15] for expression we have developed a large-scale fermentation protocol which produces significantly higher levels of functional A2AR than the equivalent volume of culture using published shaker flask protocols [15,16]. This study has also identified a C-terminally truncated version of the A2AR receptor which is more highly expressed and more stable than the WT. This construct may be more suitable for downstream functional and structural studies.

Methods

Materials

Yeast nitrogen base and yeast extract were purchased from Difco, peptone and L-histidine from Sigma-Aldrich and dimethyl sulfoxide (DMSO) from Acros Organics. Com-
plete EDTA-free protease inhibitor cocktail tablets were purchased from Roche and the bicinchoninic acid assay (BCA) kit purchased from Pierce. Scintillation cocktail (Ultima Gold MV) was obtained from PerkinElmer. [3H]ZM 241385 was obtained from American Radiolabelled Chemicals Inc. while ZM241385 was obtained from Tocris and Theophylline from Fisher Scientific. Nitrocellulose membrane was obtained from Millipore and GF/B filters were from Whatman. The mouse M2 anti-FLAG antibody was from Sigma-Aldrich and the sheep anti-mouse IgG-horseradish peroxidase (HRP) conjugate from GE Healthcare. All other chemicals were obtained from Sigma-Aldrich.

Expression constructs

The WT A2AR was expressed using a modified pPIC9K (Invitrogen) vector incorporating a Flag tag followed by a 10 His tag and a TEV cleavage site all upstream of the gene coding for the receptor as described by Andre et al., [15]. This vector was further modified to remove the Bio-tag located downstream of the gene coding for the receptor. The forward primer 5'-GGT GGA TCC ATG CCC ATC ATG containing a stop codon after residue V334 was used to amplify the truncated A2AR gene fragment. This amplified gene fragment was sequenced and cloned into the truncated A2AR gene fragment. This amplified gene fragment was sequenced and cloned into the BamHI and SpeI restriction sites of the modified pPIC9K (Invitrogen) vector. Expression plasmids were transformed by electroporation into SMD1163 P. pastoris cells.

Small scale cultures

Single P. pastoris colonies containing the plasmid of interest were selected on YPD plates [1% (w/v) yeast extract, 2% (w/v) peptone, 2% (w/v) dextrose, 2% (w/v) agar] containing 0.25% geneticin. Cells from a single colony were used to inoculate 5 ml of BMGY medium [100 mM potassium phosphate pH 6.0, 1% (w/v) yeast extract, 2% (w/v) peptone, 1.34% (w/v) yeast nitrogen base without amino acids, 0.00004% (w/v) biotin, 1% (w/v) glycerol]. The culture was grown overnight at 30°C to an OD600 of 12–15. The cells were spun down at 3,000 g for 5 mins. The cell pellet was resuspended in typically 10 ml BMMY containing 2.2% (w/v) iron sulphate, 0.02% (w/v) biotin, 0.7% (w/v) zinc chloride, 0.05% (w/v) manganese sulphate, 0.02% (w/v) copper sulphate, 0.008% (w/v) sodium iodide, 0.3% (w/v) magnesium sulphate) containing 2% (w/v) glycerol and 1 ml/L PMT4 trace elements solution (0.2% (w/v) copper sulphate, 0.008% (w/v) sodium iodide, 0.3% (w/v) manganese sulphate, 0.02% (w/v) copper chloride, 0.002% (w/v) boric acid, 0.05% (w/v) calcium sulphate, 0.05% (w/v) cobalt chloride, 0.7% (w/v) zinc chloride, 2.2% (w/v) iron sulphate, 0.02% (w/v) biotin, 1 ml/L sulphuric acid). During a second growth phase the culture was fed 50% glycerol at a rate of 3.5 ml/L/h until the OD600 reached approximately 75 (~3–4 h). The temperature of the vessel was then reduced to 22°C and the cells harvested by centrifugation at 5000 g for 5 mins. The highest expressing clones were selected by Western blot for further study.

Flask cultures

Single P. pastoris colonies from high expressing clone were selected on YPD plates containing 0.25% geneticin. Cells from a single colony were used to inoculate 50 ml of BMGY medium. The culture was grown overnight at 30°C to an OD600 of 3–5. A total of 500 ml of BMGY was inoculated with 25 ml of the starter culture and grown for 6–8 h to an OD600 of 5–10. The cells were spun down at 3,000 g for 20 min and the cell pellet was resuspended in 500 ml BMMY. The culture was incubated for 20 h at 22°C and then the cells harvested by centrifugation. Samples (1 ml) were taken at various time points during expression (0, 4, 14, 16, 18, 20 hours post induction). The cells were harvested and stored at -80°C for further analysis.

Bioreactor cultures

Single P. pastoris colonies containing the plasmid of interest were selected on YPD plates containing 0.25% geneticin. Cells from a single colony were used to inoculate a 150 ml (or 500 ml for inoculation of a 20 L bioreactor vessel) starter culture of MGY medium (0.1 M potassium phosphate pH 6, 1.34% yeast nitrogen base, 0.0004% biotin, 1% glycerol). The culture was grown at 30°C with aeration for 18–22 hours to an OD600 ~10–15. The entire inoculum was added to a 5 L fermenter vessel at t = 0. Cultures were grown in a 5 L bioreactor vessel controlled by an ADI 1010 bio-controller connected to a PC running BioExpert software (all from Applikon Biotechnology). A methanol sensor (Raven Biotech) was used to control the external peristaltic pump and adjust methanol concentration to the set point. Agitation was set at 1000 rpm, pH at 5.0 and DO2 at 35% for the entire run. For the initial cell growth phase the temperature was set at 30°C. In this initial phase, the culture was allowed to consume all the glycerol contained in the 4 L of FM22 culture medium (4.3% (w/v) monobasic potassium phosphate, 0.5% (w/v) ammonium sulphate, 0.1% (w/v) calcium sulphate, 1.43% (w/v) potassium sulphate, 1.17% (w/v) magnesium sulphate) containing 2% (w/v) glycerol and 1 ml/L PMT4 trace elements solution (0.2% (w/v) copper sulphate, 0.008% (w/v) sodium iodide, 0.3% (w/v) manganese sulphate, 0.02% (w/v) copper chloride, 0.002% (w/v) boric acid, 0.05% (w/v) calcium sulphate, 0.05% (w/v) cobalt chloride, 0.7% (w/v) zinc chloride, 2.2% (w/v) iron sulphate, 0.02% (w/v) biotin, 1 ml/L sulphuric acid). During a second growth phase the culture was fed 50% glycerol at a rate of 3.5 ml/L/h until the OD600 reached approximately 75 (~3–4 h). The temperature of the vessel was then reduced to 22°C and the cells treated with a 0.1% v/v aliquot of 100% methanol supplemented with 4 ml/L PMT4, 3% DMSO, 0.04% histidine and the methanol sensor signal allowed to stabilise. The signal output was recorded in mV and the methanol feed-
ing system set point was set to this value. The culture was allowed to adapt to 0.1% methanol for 5 h. For the induction stage, the methanol concentration was raised to 0.5% v/v in steps of 0.1% v/v every 2 to 3 hours. At the end of the induction period (~18 h) the cells were harvested by centrifugation at 3,000 g for 5 min. Samples (1 ml) were taken at various time points during the culture (6, 4 and 2 hours pre induction and 0, 3, 6, 9, 12, 15, 18, and 21 hours post induction). The cells were harvested and stored at -80°C for further analysis.

Membrane preparation
Cells were resuspended in ice-cold breaking buffer (50 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 10% (w/v) glycerol, 2 mM EDTA, 1 mM PMSF, 300 nM ZM241385, (1/100 ml) PI), and broken using a tissue lyser (Qiagen) set to 30 MHz for 15 mins. Cell debris, including intact cells, were removed by a low speed spin (3,000 g) for 10 min. The supernatant was retained, and membranes isolated by centrifugation at 100,000 g for 30 min. Each membrane pellet was re-dissolved in a membrane buffer (50 mM HEPES-NaOH pH 7.4, 100 mM NaCl, 10% (w/v) glycerol) and flash frozen in liquid nitrogen for storage.

Radioligand binding assays
All radioligand binding assays were performed using the A2AR antagonist [3H] ZM241385 in binding buffer (20 mM HEPES, 1 mM EDTA, 1 mM EGTA, 0.1% BSA, pH 7.4). Single-point binding assays on yeast membrane-bound receptor contained 2 μg of membrane protein in a final volume of 1 ml in the presence of a saturating concentration (4 nM) of radioligand at 25°C for 3 hours. Non-specific binding was determined in the presence of 10 μM theophylline, an A2AR antagonist and for each concentration (4 nM) of radioligand at 25°C for 3 hours. None-specific binding was determined in the presence of 10 μM theophylline, an A2AR antagonist and for each time-point the assay was performed in triplicate. Following incubation, bound and free radioligands were separated on Whatman GF/B filters using a cell harvester (Brandel). The filters were washed three times with ice-cold phosphate buffered saline, and the amount of bound radiolabel assessed using a LS 6500 scintillation counter (Beckman Coulter). Binding data were analysed by non-linear least squares fitting using the computer package GraphPad Prism.

Protein concentration
All protein concentrations were determined by Lowry assay using bovine serum albumin as standard [26].

SDS-PAGE and Western blotting
For Western-blot analysis the proteins were separated on a 4–12% Bis-Tris NuPAGE gel prior to transfer to a PVDF membrane using the X-Cell system (Invitrogen). The blot was probed with 1:10,000 dilution of primary anti-FLAG M2 (Sigma) antibody followed by a 1:10,000 dilution of secondary goat anti-mouse horseradish peroxidase anti-body. Protein bands were visualised using ECL substrate (GE Biosciences).

Results
Bioreactors allow controlled cell growth
Figure 1 shows the changes in two parameters: dissolved oxygen (dO2) and OD600 during a sample bioreactor culture for both WT A2AR (A) and V334 A2AR (B) constructs. The initial glycerol batch phase (phase 1) showed a gradual decrease in dissolved oxygen (dO2) levels followed by a stabilisation at 35%, the configured set point. As the cells multiply and consume glycerol, the culture’s requirement for oxygen increased, lowering the observed DO2 in the vessel. Once the 35% set point was reached, the system maintained dO2 levels by modulating the airflow. This ensured the culture did not starve of oxygen until all the batch glycerol was exhausted. This phase lasted approximately 22 hours with minor differences depending on the OD600 of the starting inoculum. A sharp rise in dO2 after ~19 h cultivation indicated that the cells were starving for glycerol and did not require oxygen to metabolise the carbon source. The glycerol fed-batch phase (phase 2 on Figure 1) was then initiated. The culture was fed 50% glycerol at 3.5 ml/l/hour until the OD600 reached approximately 75. This caused dO2 levels to drop and stabilise again at 35%. This phase lasted between 3 and 4 hours. The culture was then allowed to consume any remaining glycerol before the start of the induction phase. Protein expression was induced by the addition of methanol. An adaptation period of 3–5 hours was required during which the cells alter their metabolism to accept methanol as the new carbon source. This was observed as a steady decrease in dO2 levels as the cells slowly adapt to methanol utilisation. During this phase the OD600 remained relatively stable at about 75 for the WT A2AR construct while typically a small increase was observed for the V334 A2AR (from 75 to ~80). The highly similar dO2 and OD600 traces for the two different constructs demonstrate the reproducibility of the bioreactor culture protocol described in this study.

Western blot analysis of WT A2AR and V334 A2AR expressed in flask and bioreactor cultures
Expression of the two different receptors during the induction phase for both flask and bioreactor cultures was monitored using both Western blot analysis and radioligand binding assay. Western blot analysis of flask cultures expressing WT A2AR showed a gradual increase in expression over the course of the induction phase with receptor protein first detectable at 14 hours post induction (Figure 2A) as a band of approximately 38 kDa. Several larger bands are also visible. These are likely to be due to different oligomeric forms of the receptor formed as a result of gel running conditions rather than representing the true state of the receptor. Due to the large gap in sampling
Figure 1
Comparison of key bioreactor culture parameters. Changes in OD$_{600}$ (dashed line) and dissolved oxygen (solid line) over time during the bioreactor culture of the (A) WT A$_{2x}$R and (B) V334 A$_{2x}$R are indicated. Time periods indicated by the numbers correspond to (1) glycerol batch phase (2) glycerol fed-batch phase and (3) methanol induction phase.
Figure 2
Expression of the A2AR constructs over time. Western blot analysis of WT A2AR (A) and V334 A2AR (B) expressed in flask and WT A2AR (C) and V334 A2AR (D) in bioreactor cultures. Analysis was performed on membranes prepared from cells harvested at the different time points using anti-Flag antibody. M denotes the molecular weight markers and the numbers along the top of blots correspond to the time points.
times it is likely that receptor is expressed before 14 hours, however it is clear that no receptor is expressed at 4 hours post induction. The amount of WT A2AR did not seem to significantly increase after this. The V334 A2AR expressed in flasks (Figure 2B) was first detected as a band of approximately 28 kDa at a similar time point however the amount of protein increased significantly after this to the 20 hour time point where the culture was harvested. Expression of the WT A2AR in the bioreactor also increased with time although the expression was detectable by Western blot at 3 hrs in contrast to the flask cultures (Figure 2C). A similar trend is observed for the V334 A2AR (Figure 2D). There were some low molecular weight bands visible for the WT A2AR, indicating that there is proteolytic degradation of the expressed receptor. The fact that these bands are being detected using the N-terminally positioned Flag tag suggests that the bands observed are due to C-terminal degradation. This is not observed in the flask culture for either construct, or the bioreactor culture expressing the V334 A2AR. Interestingly however there is a distinctive band visible at ~45 kDa for the V334 A2AR bioreactor samples which is not present in the flask culture for the same construct. It is possible that the higher levels of expression detected for the V334 A2AR in the bioreactor stimulates a larger amount of dimer formation in the membrane.

Functional analysis of WT A2AR and V334 A2AR expressed in flask and bioreactor cultures

Radioligand binding analysis indicated a similar trend in increasing expression of functional receptor from the flask cultures. There was no measurable functional receptor for the first 4 hours post induction (Figure 3A) while after this time functional expression increased rapidly, as measured at 14 hours. In the case of the WT A2AR the expression level does not increase much after 14 hours with a final expression level of 23 pmol/mg. The A2AR V334 construct expresses to a much higher level after 14 hours (53 pmol/mg) and increases significantly after that to a final expression level of 72 pmol/mg after 20 hour (Figure 3A). The expression profile is slightly different in the case of the bioreactor cultures. Derepression of the methanol promoter due to depletion of the glycerol during the second growth phase, induces expression from the AOX1 promoter resulting in low level but measurable receptor production prior to induction. For both the WT A2AR and the V334 receptor constructs there is a steady increase in expression up to 6 hours post induction (Figure 3B). After this time the expression of the WT A2AR continues to increase steadily peaking at approximately 125 pmol/mg at the end of the culture (18 hrs) while A2AR V334 increases much faster peaking at 250 pmol/mg at 18 hrs (Figure 3B). The culture for the V334 construct was continued for a further 3 hours however the data suggests that this results in a slight drop in functional expression. It may be that 18 hrs is the optimal harvesting time for the bioreactor cultures.

Discussion

Flask versus bioreactor expression

The main aim of the study was to compare the expression of A2AR in flask and bioreactor based cultures. The flask conditions used in this study were similar to, or the same, as those which have previously been used for expression of the A2AR in P. pastoris [15,16]. Flask cultures enable the exploration of several expression conditions in parallel and require a limited set-up compared to bioreactor based cultures. However there are a number of drawbacks to flask cultures, which the bioreactor is particularly well suited to overcome. The principal advantage of the biore-
actor set up is that it enables large volumes of air to be circulated within the culture to satisfy the high oxygenation requirements of \( P. \) \( \text{pastoris} \) cultivation to high OD\(_{600}\). The ability to regulate pH and dissolved oxygen (dO\(_2\)) was shown to greatly improve batch-to-batch reproducibility while glycerol and methanol feeding lines enable accurate control over the amount of nutrients added to the culture. \( P. \) \( \text{pastoris} \) synthesises alcohol oxidase 1 (AOX1), which metabolises methanol by conversion to formaldehyde. However, if high concentrations of methanol are introduced without pre-conditioning of the culture to this carbon source, excess formaldehyde can accumulate to toxic levels to the cells [27]. It is therefore very important to allow the culture to adapt to methanol utilisation using low methanol concentration. Initial inductions performed in the absence of accurate methanol control systematically produced very erratic expression profiles (data not shown). The implementation of a methanol control system proved essential for the reliability and reproducibility of receptor expression.

The cell density achieved in the bioreactor cultures was routinely almost six times higher than that achieved in flask cultures as assessed by measurement of the OD\(_{600}\). In addition radioligand binding indicated that there was an approximately three and a half times higher functional expression for the bioreactor culture compared to the flask culture (summarised in Table 1). Thus the expression level in the bioreactor is increased in two ways; 1) the biomass is increased and 2) the production of functional receptor is increased per mg of membrane protein. These data clearly demonstrate the high efficiency receptor production that can be achieved by the careful regulation and optimisation of the growth parameters possible in bioreactor cultures. It is likely that the protocol described here is suitable for large scale production of other GPCRs in bioreactors since increases in functional expression level have also been obtained for the human dopamine D2 and the human serotonin 5HT1D receptors compared to flask cultures (data not shown).

Protein expression in the absence of inducer, so-called leaky expression, is often observed when using recombinant systems [28]. The binding assay results indicated that in the case of both the WT and V334 A2AR expressed in bioreactors, receptor was present prior to methanol induction. Glycerol represses the AOX1 promoter used for A2AR expression and therefore no receptor should be detected prior to the addition of methanol. However, as the culture is allowed to fully deplete the glycerol present in both glycerol batch and glycerol fed-batch phases, some degree of derepression can occur, allowing some protein to be synthesised. Ligand binding analysis also indicated the presence of small amounts of receptor (maximally ~25 pmol/mg) in bioreactor samples taken prior to induction with methanol. From published data, no more than 2–4% of the total attainable amount of AOX1 induced protein is normally produced through derepression [29]. Interestingly, according to our measurements, an estimated 10–15% receptor was produced in starvation conditions. Functional analysis of the receptor produced as a result of derepression indicates that A2AR produced during derepression is correctly folded and functional. The relatively low OD\(_{600}\) values achieved in flask cultures mean it is unlikely that all the glycerol is consumed in the glycerol batch phase explaining why no expression is detectable at induction (time = 0 hours) due to derepression of the AOX1 promoter.

**WT A2AR versus V334 A2AR functional expression**

Radioligand binding analysis indicated that higher levels of receptor were produced for the truncated V334 A2AR compared to the WT A2AR in both flask and bioreactor cultures with the V334 A2AR expressing at approximately double the amount of the WT receptor (Table 1). The B\(_{\text{max}}\) value of 200 pmol/mg achieved for the V334 A2AR is the highest reported value for functional expression of the A2AR in \( P. \) \( \text{pastoris} \). This is lower than that achieved for expression of the A2AR in both \( S. \) \( \text{cerevisae} \) (480 pmol/mg; [23]) and mammalian cells (287 pmol/mg; [30]). However the higher cell densities achieved using \( P. \) \( \text{pastoris} \) mean that higher expression levels per litre are obtained. Smaller bioreactors are required for \( P. \) \( \text{pastoris} \) growth than for \( S. \) \( \text{cerevisae} \) making the cultures both cheaper and easier to handle.

Numerous studies have indicated that C-terminal truncation of GPCRs produces a much more stable protein, more suitable for structural studies [24,25]. Western blot analysis of the WT A2AR expressed in the bioreactor indicated the presence of degradation bands likely to be the result of C-terminal degradation. This is a major concern.

**Table 1: Cell densities and specific binding for the A2AR constructs expressed in flask and bioreactor cultures**

| Construct   | Cell density (OD\(_{600}\))* | Maximum specific binding (pmol/mg) |
|-------------|------------------------------|-----------------------------------|
|             | Flask                        | Bioreactor                        |
|             |                              | Flask                             | Bioreactor                       |
| WT A2AR     | 14                           | 75                                | 32.5 ± 9.3                       | 112.5 ± 2.7             |
| A2AR V334   | 14                           | 80                                | 82.9 ± 11.2                      | 200.6 ± 17.6             |

* cell density at induction
since the His-tag to be used for immobilised metal affinity chromatography is N-terminally located. Thus, purification would not differentiate between intact and degraded receptor. In contrast the V334 A2AR does not exhibit this degradation during expression. Previous studies expressing the WT A2AR in E. coli demonstrated C-terminal degradation upon solubilisation [22]. In addition, work in our group has shown C-terminal degradation of the WT A2AR expressed in P. pastoris upon purification to high homogeneity (Singh et al, manuscript in preparation). These data indicate an intrinsic instability in the WT A2AR. This degradation has not been previously reported for expression of the receptor in relatively small scale P. pastoris cultures [16] and this is supported by the findings of this study since no degradation bands were observed for either construct in flask cultures. It may be that the very high expression levels achieved in the bioreactor reduces the processing and targeting time of the receptor making it more vulnerable to degradation by intracellular proteases. The lack of degradation of the V334 A2AR indicates that this is more stable and therefore a more suitable candidate for further downstream structural and functional studies. Recent work by Magnani et al, [31] describes the identification of a number of mutants of the human A2AR with increased thermostability and increased stability in short chain detergents making them more suitable for crystallisation. Mutant screening was performed in E. coli, however it may be that the use of a eukaryotic system like the large-scale P. pastoris system described in this manuscript is more suitable for the production of the mutant receptors for structural studies.

Conclusion
The use of P. pastoris bioreactor cultures has significant advantages over traditional flask cultures for the expression of GPCRs for functional and structural studies. Bioreactors yield higher cell densities as well as higher levels of functional A2AR per mg of membrane protein compared to flask cultures. Greater control of both cell growth and induction conditions allow much greater reproducibility of receptor expression. This study has also identified a more stable truncated V334 A2AR construct for further functional and structural studies.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SS and PGS carried out all the radioligand binding assays, SS, AG, CF-V and MM optimised the bioreactor running conditions, AG, CF-V and MM performed the flask cultures for comparison, RR, MM and AG optimised the Western blots, RW and JR made the expression constructs while RW developed the flask expression conditions, BB designed the research and wrote the manuscript.

Acknowledgements
We thank James Mansfield for technical assistance. This research was funded by the Biological and Biophysical Research Council, the Membrane Protein Network (MePNet), the European Membrane Protein Consortium (E-MeP), and the French government (Association Nationale de la Recherche Technique).

References
1. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002, 1:727-30.
2. Klabunde T, Hessler G: Drug design strategies for targeting G-protein-coupled receptors. ChemBiochem 2002, 3:928-44.
3. Tate CG, Grisshammer R: Heterologous expression of G-protein-coupled receptors. Trends Biotechnol 1996, 14:426-30.
4. Chelikani P, Reeves Pj, Rajbhandary Ul, Khourana HG: The synthesis and high-level expression of a beta2-adrenergic receptor gene in a tetracycline-inducible stable mammalian cell line. Protein Sci 2006, 15:1433-40.
5. Lundstrom K, Wagner R, Reinhardt H, Desmyter A, Cherouati N, Magdin T, Zeder-Lutz G, Courrot M, Prual C, Andre N, Hasaige G, Miodu H, Camillibus C, Khorana HG: Membrane proteins: comparison of more than 100 GPCRs in 3 expression systems. J Struct Funct Genomics 2006, 7:77-91.
6. Long SB, Campbell EB, Mackinnon R: Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 2005, 309:897-903.
7. Cregg JM, Vedvick TS, Raschke WC: Recent advances in the expression of foreign genes in Pichia pastoris. Biotechnology (N Y) 1993, 11:905-10.
8. Sreekrishna K, Brankamp RG, Kropp KE, Blankenship DT, Tsay JT, Smith PL, Wierschke JH: Strategies for optimal synthesis and secretion of heterologous proteins in the methlyotrophic yeast Pichia pastoris. Gene 1997, 190:55-62.
9. Reilander H, Weiss HM: Production of G-protein-coupled receptors in yeast. Curr Opin Biotechnol 1998, 9:507-10.
10. Cereghino JL, Cregg JM: Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEBS Microbiol Rev 2000, 24:45-66.
11. Weiss HM, Haase W, Michel H, Reilander H: Expression of functional mouse 5-HT5A serotonin receptor in the methylotrophic yeast Pichia pastoris: pharmacological characterization and localization. FEBS Lett 1995, 377:451-6.
12. Weiss HM, Haase W, Michel H, Reilander H: Comparative biochemical and pharmacological characterization of the human mu opioid receptor expressed in Pichia pastoris. Protein Expr Purif 2005, 43:85-93.
13. Sarramegna V, Muller I, Mousseau G, Froment C, Monsarrat B, Milan A, Talmont F: Solubilization, purification, and mass spectrometry analysis of the human mu-oidip receptor expressed in Pichia pastoris. Protein Expr Purif 2005, 43:85-93.
14. André N, Cherouati N, Prual C, Steffen T, Zeder-Lutz G, Magdin T, Patrus F, Michel H, Wagner R, Reinhardt C: Enhancing functional expression of G protein-coupled receptors in Pichia pastoris to levels required for structural studies via a single expression screen. Protein Sci 2006, 15:1115-26.
15. Fraser NJ: Expression and functional purification of a glycyl-sylation deficient version of the human adenosine 2a receptor for structural studies. Protein Expr Purif 2006, 49:129-37.
16. Murata Y, Watanabe T, Sato M, Momose Y, Nakahara T, Oka S, Iwashita H: Dimethyl sulfoxide exposure facilitates phospholipid biosynthesis and cellular membrane proliferation in yeast cells. J Biol Chem 2003, 278:33185-93.
17. Cereghino GP, Cereghino JL, Ilgen C, Cregg JM: Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris. Curr Opin Biotechnol 2002, 13:329-32.
19. Zhang W, Smith LA, Plantz BA, Schlegel VL, Meagher MM: *Design of methanol feed control in Pichia pastoris fermentations based upon a growth model*. Biotechnol Prog 2002, 18:1392-9.

20. Mattanovich D, Gasser B, Hohenblum H, Sauer H: *Stress in recombinant protein producing yeasts*. J Biotechnol 2004, 113:121-35.

21. Linden J: *Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection*. Annu Rev Pharmacol Toxicol 2001, 41:775-787.

22. Weiss HM, Grisshammer R: *Purification and characterization of the human adenosine A(2a) receptor functionally expressed in Escherichia coli*. Eur J Biochem 2002, 269:82-92.

23. O'Malley MA, Lazarova T, Britton ZT, Robinson AS: *High-level expression in Saccharomyces cerevisiae enables isolation and spectroscopic characterization of functional human adenosine A2a receptor*. J Struct Biol 2007, 159:166-78.

24. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC: *High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor*. Science 2007, 318:1258-65.

25. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AG, Tate CG, Schertler GF: *Structure of a [beta]1-adrenergic G-protein-coupled receptor*. Nature 2008, 454:486-91.

26. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: *Protein measurement with the Folin phenol reagent*. J Biol Chem 1951, 193:265-75.

27. Guarna MM, Lesnicki GJ, Tam BM, Robinson J, Radziminski CZ, Hasenwinkle D, Boraston A, Jervis E, Macgillivray RT, Turner RF, Kilburn DG: *On-line monitoring and control of methanol concentration in shake-flask cultures of Pichia pastoris*. Biotechnol Bioeng 1997, 56:279-86.

28. Saida F, Uzan M, Odaert B, Bontems F: *Expression of highly toxic genes in E. coli: special strategies and genetic tools*. Curr Protein Pept Sci 2006, 7:47-56.

29. Tschopp JF, Brust PF, Cregg JM, Stillman CA, Gingeras TR: *Expression of the lacZ gene from two methanol-regulated promoters in Pichia pastoris*. Nucleic Acids Res 1987, 15:3859-76.

30. Hassaine G, Wagner R, Kempf J, Cherouati N, Hassaine N, Prual C, André N, Reinhart C, Pattus F, Lundstrom K: *Semliki Forest virus vectors for overexpression of 101 G protein-coupled receptors in mammalian host cells*. Protein Expr Purif 2006, 45:343-51.

31. Magnani F, Shibata Y, Serrano-Vega MJ, Tate CG: *Co-evolving stability and conformational homogeneity of the human adenosine A2a receptor*. Proc Natl Acad Sci USA 2008, 105:10744-9.